
Emax and EC50 identifiability in an indirect-response model
October 27, 2026
Is \(EC_{50}\) estimable at all, and if so, from what?
⚠️ \(EC_{50}\) is estimable only through \(E_{\max}\), and \(E_{\max}\) only from the first days of depletion, or from a cohort held in a narrow concentration band far below \(EC_{50}\).
\[ \frac{dB}{dt} = k_{\rm out} B_0 - k_{\rm out}\big(1 + E(C)\big) B \]
\[ E(C) = \frac{E_{\max} C}{EC_{50} + C} \]
\[ C(t) = \frac{D}{V} e^{-k_e t} \]

| Symbol | What it is | Value | Why |
|---|---|---|---|
| \(B_0\) | Baseline B-cell count | 200 cells/µL | Ofatumumab model 194, inebilizumab 135 |
| \(k_{\rm out}\) | B-cell loss rate | 0.02 per day | Half-life 35 d; ofatumumab 0.0124/d |
| \(E_{\max}\) | Maximum fold-increase in loss | 150 | Ofatumumab 159, paediatric rituximab 155 |
| \(EC_{50}\) | Concentration for half of \(E_{\max}\) | 1 mg/L | Arbitrary scale |
| \(V\), \(CL\) | Volume, clearance | 3 L, 0.2 L/day | Half-life 10.4 d, an IgG1 |
| LOQ | Flow-cytometry limit | 5 or 10 cells/µL | 2.5% or 5% of baseline |
| \(\sigma\) | Proportional residual error | 30% | Inebilizumab model 61% |
Published values are transcribed from the papers and not yet checked by eye.
Single dose with \(C_{\max} = 100 \times EC_{50}\). Dashed line: limit of quantification at 5% of baseline.
\[ \frac{d \ln B}{dt} = k_{\rm out} \left( \frac{B_0}{B} - 1 - E(C) \right) \]
| \(k_{\rm out}(1+E)\) | Compared with \(k_e = 0.067\)/day | So \(B\) | |
|---|---|---|---|
| Start, \(E = E_{\max}\) | 3.0 per day | 45 times faster | follows the drug |
| End, \(E = 0\) | 0.02 per day | 0.3 times as fast | lags, returns at its own pace |
The curve starts fast and ends slow, so its parts separate.
For \(t \ll 1/k_e\) the concentration is still near \(C_{\max}\), so the equation is linear with constant coefficient:
\[ B(t) = B_{\rm ss} + (B_0 - B_{\rm ss})\, e^{-k_f t}, \qquad k_f = k_{\rm out}\big(1 + E(C_{\max})\big) \]
\[ t_{1/2,\rm fall} \approx \frac{\ln 2}{k_{\rm out}(1 + E_{\max})} \quad \text{for } C_{\max} \gg EC_{50} \]
After the fall, \(B\) tracks the quasi-steady state:
\[ B(t) \approx \frac{B_0}{1 + E\big(C(t)\big)} \approx \frac{B_0}{1 + E_{\max}} \quad \text{while } C \gg EC_{50} \]
The count crosses \(f B_0\) when \(E(C) = (1 - f)/f\). With \(C = C_{\max} e^{-k_e t}\):
\[ t_f = \underbrace{\frac{1}{k_e} \ln \frac{f\, S_0\, C_{\max}}{1 - f}}_{S_0 \text{ only}} + \underbrace{\frac{1}{k_e} \ln\left(1 - \frac{1 - f}{f E_{\max}}\right)}_{E_{\max} \text{ alone}} \]
Tail. Once \(S_0 C \ll 1\), the model is \(dB/dt = k_{\rm out}(B_0 - B)\):
\[ B_0 - B(t) \propto e^{-k_{\rm out} t} \qquad \text{(needs } k_{\rm out} < k_e\text{)} \]
Doses that stay below \(EC_{50}\). \(E(C) \approx S_0 C\) for the whole curve, so the model holds \(E_{\max}\) and \(EC_{50}\) only as their ratio. For shallow depletion:
\[ \varepsilon_{\max} = 1 - \frac{B_{\min}}{B_0} = S_0 C_{\max} \left(\frac{k_{\rm out}}{k_e}\right)^{k_e/(k_e - k_{\rm out})} \]
\[ \text{area} = \int_0^\infty (B_0 - B)\,dt \;\sim\; \frac{B_0}{k_e} \frac{E_{\max}}{1 + E_{\max}} \ln\left(1 + \frac{C_{\max}}{EC_{50}}\right) \quad \text{(large dose)} \]
| Cmax | Emax | EC50 | Area, ODE | Large-dose formula |
|---|---|---|---|---|
| 1 | 50 | 0.33 | 21407 | 4077 |
| 1 | 150 | 1.00 | 21715 | 2066 |
| 1 | 450 | 3.00 | 21818 | 861 |
| 100 | 50 | 0.33 | 34999 | 16786 |
| 100 | 150 | 1.00 | 35481 | 13754 |
| 100 | 450 | 3.00 | 35631 | 10585 |
Forty random parameter sets: \(E_{\max}\) 30 to 1000, \(EC_{50}\) 0.1 to 10, \(k_{\rm out}\) 0.005 to 0.04 per day. Largest misses are where \(C_{\max}\) is only 30 × \(EC_{50}\) or \(k_{\rm out}\) is small.
| Part of the curve | Carries | Observed when | Usual B-cell study |
|---|---|---|---|
| Baseline | \(B_0\) | always | ✅ |
| Fall | \(k_{\rm out}(1 + E_{\max})\) | samples in the first one to two days | ❌ first sample at a week |
| Floor | \(E_{\max}\) | \(E_{\max} < 1/f - 1\) | ❌ below the limit |
| Climb back | \(S_0\), plus a few-day \(E_{\max}\) term | samples through recovery, PK known | ✅ |
| Tail | \(k_{\rm out}\) | samples until repopulation | ✅ |
| Low-dose cohort | \(S_0\), \(k_{\rm out}\) | \(C_{\max} \ll EC_{50}\) | ✅ but adds no \(E_{\max}\) |
The model is structurally identifiable. The loss is practical, caused by the quantification limit and the sampling schedule.
Sharma and Jusko (1998), Table 1, recover the parameters graphically:
Design: two or more bolus doses, one high enough for full effect, and the baseline.
Three-fold differences in \(E_{\max}\) and \(EC_{50}\) at fixed ratio. Above the limit the curves differ in the first two days and nowhere else.
\[ \frac{B_{ss}}{B_0} = \frac{1}{1 + E(C)} \]
Half of baseline needs \(E = 1\):
\[ C_{1/2} = \frac{EC_{50}}{E_{\max} - 1} \]

| Design | First sample | RSE Emax % | RSE EC50 % | corr(Emax, EC50) | RSE Emax/EC50 % | RSE k_out % |
|---|---|---|---|---|---|---|
| A: 300 mg, 6 patients | Day 1 | 41 | 55 | 0.94 | 21 | 39 |
| B: 30, 100, 300 mg; 4 each | Day 1 | 26 | 34 | 0.94 | 13 | 24 |
| C: 3 to 300 mg, five levels; 4 each | Day 1 | 12 | 13 | 0.83 | 7 | 10 |
| D: C with 0.03, 0.3 mg for 10, 100 | Day 1 | 10 | 9 | 0.72 | 7 | 8 |
| A: 300 mg, 6 patients | Day 7 | 833 | 894 | 1.00 | 65 | 56 |
| B: 30, 100, 300 mg; 4 each | Day 7 | 127 | 144 | 1.00 | 21 | 28 |
| C: 3 to 300 mg, five levels; 4 each | Day 7 | 109 | 123 | 1.00 | 17 | 20 |
| D: C with 0.03, 0.3 mg for 10, 100 | Day 7 | 90 | 98 | 1.00 | 11 | 9 |
Fisher information, LOQ 5 cells/µL, 30% proportional error, observations below the limit dropped.
| Drug | Data | What happened to \(EC_{50}\) |
|---|---|---|
| Ofatumumab | 1,486 patients, 3 to 700 mg, partial-depletion arms at 3 and 10 mg SC | ✅ Estimated, RSE 8.5%; \(E_{\max}\) 159 |
| Rituximab, paediatric | 63 patients, full dose, 52% of counts below limit | ⚠️ \(ED_{50}\) RSE 61%, CI 0.18 to 2.26 mg |
| Inebilizumab | 213 subjects, 100-fold dose range | ❌ Abandoned for a log-linear slope |
| Rituximab, membranous nephropathy | 41 patients | ❌ None; TMDD binding constant at 60% RSE |
| Ianalumab | Phase 2 and RA data | ❌ Not reported; receptor-occupancy model added |
Values transcribed from the papers by a fetch tool, not yet checked by eye.
Schoemaker, van Gerven and Cohen (1998): when the data do not approach \(E_{\max}\), report \(S_0 = E_{\max}/EC_{50}\).
The duration of depletion depends on \(S_0\) and \(k_{\rm out}\), so a slope model loses nothing inside the studied dose range.
In the order they would be dropped from a protocol:
Full list with status markers: references. Working document: EC50 identifiability.